Michael Goettler is currently Executive Vice President, Pfizer and is a member of the Company’s Executive Leadership Team. In this role, he will be responsible for the newly created Established Medicines business, effective fiscal year 2019. With more than 23 years in the pharmaceutical industry, Michael has extensive commercial leadership experience and has lived and worked in multiple markets and regions, in both Asia/Pacific and Europe.
Michael joined Pfizer in 2009, as part of the Wyeth acquisition and has held a number of senior leader roles at both Wyeth and Pfizer with increasing responsibility across multiple therapeutic areas, including primary and specialty care. Most recently, he served as the Global President of Pfizer Inflammation & Immunology, leading Pfizer’s global five-billion-dollar portfolio of inline medicines, as well as late-stage, early development and research strategy and programs spanning rheumatology, dermatology and gastroenterology. Before then, he led Pfizer Rare Disease, where he initiated the company’s commercial move into gene therapy.
Prior to Wyeth, Michael held a variety of senior roles at Sanofi Aventis in the US and Japan in business development, eBusiness and global marketing.
Michael began his career working at Hoechst in Germany, where he quickly moved into roles of increasing responsibility, including Executive Vice President ＆ CEO of Hoechst Marion Roussel Korea.
A native German, Michael studied in Germany, France and the US. He holds an M.B.A. from the University of Texas at Austin and graduated from the Koblenz School of Corporate Management in Germany, both with summa cum laude.
Michael is a member of the board of directors of PSI (Population Services International), a global health organization dedicated to improving the health of people in the developing world by focusing on serious challenges like a lack of family planning, HIV and AIDS, barriers to maternal health, and the greatest threats to children under five, including malaria, diarrhea, pneumonia and malnutrition.